PinTherapeutics

Pin Therapeutics, Inc. is a biotechnology firm established in 2019 with a focus on developing a new class of medicines based on targeted protein degradation. The company was co-founded by a team of scientists with deep expertise in the field: President and CEO Cyrus Arman, Ph.D., Chief Scientific Officer (CSO) Gerald Crabtree, M.D., and Scientific Co-founders Peter Parker, Ph.D., and Nathanael Gray, Ph.D. Dr. Crabtree is a distinguished professor at Stanford University and an investigator at the Howard Hughes Medical Institute, bringing decades of research in developmental biology and genetics. Dr. Gray is a professor in the Department of Chemical and Systems Biology at Stanford University, with a notable background in developing kinase inhibitors. Dr. Arman’s background includes roles at venture capital firms and other biotech companies, providing a blend of scientific and business acumen.

The company's core technology revolves around a proprietary platform for creating molecular glues that can induce the degradation of disease-causing proteins. This approach, known as targeted protein degradation (TPD), aims to eliminate harmful proteins entirely rather than just inhibiting their function, which is the mechanism for many traditional drugs. The platform leverages chemoproteomics to identify and validate new targets for degradation. Pin Therapeutics' initial focus is on developing therapies for oncology, particularly for cancers driven by proteins that have been historically difficult to target with conventional small molecule drugs.

The business operates within the biopharmaceutical sector, specifically in the competitive landscape of protein degrader technologies. Its primary clients are, in the long term, patients and healthcare systems, though its immediate strategic partners are likely to be larger pharmaceutical companies for collaboration or licensing agreements. The revenue model is typical for a preclinical biotech firm, relying on venture capital funding to advance its research and development programs through the costly and lengthy drug discovery and clinical trial phases, with the ultimate goal of commercializing its therapeutic products. The company secured a $26 million seed financing round to advance its platform and pipeline.

Keywords: targeted protein degradation, molecular glues, oncology therapeutics, chemoproteomics, small molecule drugs, drug discovery, preclinical biotech, cancer treatment, protein degraders, biopharmaceutical